Watch for Resmetirom to Treat NASH
July 2024
Resmetirom (Rezdiffra) will be the first med approved for treatment of nonalcoholic steatohepatitis (NASH) with fibrosis in adults.
About 5% of adults in the US have NASH.
You will start to hear NASH called metabolic dysfunction-associated steatohepatitis (MASH)...to reflect its link with cardiometabolic risk factors (diabetes, dyslipidemia, obesity, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote